Boehringer Ingelheim’s New €285m Chemical Plant to Boost Pharmaceutical Innovation

From left: Minister President Malu Dreyer, Federal Chancellor Olaf Scholz and Hubertus von Baumbach lay the foundation stone

(IN BRIEF) Boehringer Ingelheim has begun construction on a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany. The €285 million investment will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for clinical trial phases, enabling Boehringer Ingelheim to swiftly advance new drug candidates from its extensive research pipeline to clinical trials and market approval. The initiative reinforces Germany’s position as a leading research and production location for the reliable supply of medicines to patients worldwide, with Boehringer Ingelheim playing a critical role. The Chemical Innovation Plant bridges the gap between smaller pilot plants in Biberach, Germany, and Ridgefield, USA, and commercial production of active pharmaceutical ingredients for marketed products in Ingelheim.

(PRESS RELEASE) INGELHEIM, 2-May-2023 — /EuropaWire/ — Boehringer Ingelheim, one of the world’s leading research-driven pharmaceutical companies with 130 years of experience, has broken ground to construct a new Chemical Innovation Plant at its headquarters in Ingelheim, Germany, with the foundation stone laid today in the presence of German Chancellor Olaf Scholz and Rhineland-Palatinate Minister-President Malu Dreyer. The major investment of €285 million will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for clinical trial phases, enabling Boehringer Ingelheim to quickly advance new drug candidates from its vast research pipeline to clinical trials and market approval.

This initiative reinforces Germany’s position as a leading research and production location for the reliable supply of medicines to patients worldwide, with Boehringer Ingelheim playing a critical role. The investment secures the company’s long-term capacity for manufacturing new chemical entities, with biopharmaceuticals and small molecules accounting for roughly half of its research pipeline.

“Developing new drugs is a critical technology of the 21^st century. The pandemic has shown Germany’s potential in innovating and manufacturing life-saving medications. Germany and Europe can enhance their resilience by establishing local value chains. Boehringer Ingelheim’s new innovation center is excellent news,” said Federal Chancellor Olaf Scholz before the laying of the foundation stone.

“The pharmaceutical industry has a long tradition in Rhineland-Palatinate. Boehringer Ingelheim is a driver of innovation and we take great pride in the transformation of the company’s headquarters in Ingelheim into a global ‘launch site’. As the Minister-President of this region, I am thrilled to see this strong commitment to the site. The government of our state places a high priority on creating a favourable environment to enable pharmaceutical companies like Boehringer Ingelheim to keep developing and manufacturing locally. Boehringer Ingelheim is a very important partner for us,” said Minister President Malu Dreyer.

The Chemical Innovation Plant bridges the gap between smaller pilot plants in Biberach, Germany, and Ridgefield, USA, and commercial production of active pharmaceutical ingredients for marketed products in Ingelheim. The seven-floor building spans 11,500 square meters and will house four production lines with related development areas, designed for further expansion to accommodate future needs and new technologies.

“The Chemical Innovation Plant will enable us to offer life-saving, more effective therapy options to patients from our research pipeline at a faster pace,” said Hubertus von Baumbach, Chairman of the Board of Managing Directors. “We rely on innovation, research and development in Germany and Europe as part of a global value chain. By doing so, we make a substantial contribution in bolstering Germany’s status as an attractive employer, investor, sustainable producer, and thriving competitor in a global market.”

Boehringer Ingelheim

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Media Contacts:

Mark Valentiner
press@boehringer-ingelheim.com
Tel.: +49 (6132) 77-170136

SOURCE: Boehringer Ingelheim International GmbH